Moore, John P

Publications

Sort by

Co-Author Network

selected publications

Decoding epitope immunodominance in HIV Env using cryoEM and machine learning. bioRxiv : the preprint server for biology. 2026 Article GET IT
HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial. Nature communications. 2025 Academic Article GET IT
Times cited: 1
A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers. Journal of virology. 2025 Academic Article GET IT
Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science (New York, N.Y.). 2025 Academic Article GET IT
Times cited: 16
The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies. Nature reviews. Microbiology. 2025 Information Resource GET IT
Times cited: 8
Germline-targeting HIV Envelope SOSIP immunization more frequently elicits broadly-neutralizing antibody precursor responses in infant compared to juvenile rhesus macaques. bioRxiv : the preprint server for biology. 2025 Article GET IT
The RV144 Trial Might Still Yield Useful Information. Current HIV research. 2025 Academic Article GET IT
Times cited: 1
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. The Journal of experimental medicine. 2024 Academic Article GET IT
Times cited: 21
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Science immunology. 2024 Academic Article GET IT
Times cited: 27
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques. Science immunology. 2024 Academic Article GET IT
Times cited: 13
The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence. Journal of virology. 2024 Academic Article GET IT
Times cited: 4
Progress on priming HIV-1 immunity. Science (New York, N.Y.). 2024 Article GET IT
Times cited: 14
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies. medRxiv : the preprint server for health sciences. 2024 Article GET IT
Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques. bioRxiv : the preprint server for biology. 2023 Article GET IT
Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. PLoS pathogens. 2023 Academic Article GET IT
Times cited: 11
Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PloS one. 2023 Article GET IT
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Retrovirology. 2023 Academic Article GET IT
Times cited: 6
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell reports. Medicine. 2023 Academic Article GET IT
Times cited: 31
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Research square. 2023 Article GET IT
Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons. American journal of obstetrics & gynecology MFM. 2022 Academic Article GET IT
Times cited: 12
Asthma 17q21 polymorphism associates with decreased risk of COVID-19 in children. Pediatric pulmonology. 2022 Article GET IT
Times cited: 3
Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. iScience. 2022 Academic Article GET IT
Times cited: 15
Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 8
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of virology. 2022 Information Resource GET IT
Times cited: 18
Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. NPJ vaccines. 2021 Article GET IT
Times cited: 2
The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of virology. 2021 Academic Article GET IT
Times cited: 20
Beta testing the monkey model. Nature immunology. 2021 Article GET IT
Times cited: 1
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Science advances. 2021 Academic Article GET IT
Times cited: 84
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS pathogens. 2021 Academic Article GET IT
Times cited: 18
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American journal of hematology. 2021 Article GET IT
Times cited: 26
Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 21
Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. Journal of virology. 2021 Academic Article GET IT
Times cited: 7
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nature communications. 2021 Academic Article GET IT
Times cited: 55
Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging infectious diseases. 2021 Academic Article GET IT
Times cited: 49
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathogens & immunity. 2021 Academic Article GET IT
Times cited: 91
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. medRxiv : the preprint server for health sciences. 2021 Article GET IT
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. The Journal of clinical endocrinology and metabolism. 2021 Academic Article GET IT
Times cited: 24
Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA. 2021 Academic Article GET IT
Times cited: 53
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell reports. 2021 Academic Article GET IT
Times cited: 42
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science advances. 2021 Information Resource GET IT
Times cited: 86
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv : the preprint server for biology. 2021 Article GET IT
Virus vaccines: proteins prefer prolines. Cell host & microbe. 2021 Information Resource GET IT
Times cited: 79
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA. 2021 Academic Article GET IT
Times cited: 177
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 40
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosensors & bioelectronics. 2021 Academic Article GET IT
Times cited: 19
High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. eLife. 2021 Academic Article GET IT
Times cited: 20
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell reports. Medicine. 2020 Article GET IT
Times cited: 21
Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of virology. 2020 Academic Article GET IT
Times cited: 15
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. medRxiv : the preprint server for health sciences. 2020 Article GET IT
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 64
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. Journal of virology. 2020 Information Resource GET IT
Times cited: 71
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 49
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife. 2020 Academic Article GET IT
Times cited: 135
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. eLife. 2020 Information Resource GET IT
Times cited: 67
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nature medicine. 2020 Academic Article GET IT
Times cited: 141
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. Cell host & microbe. 2020 Information Resource GET IT
Times cited: 48
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Journal of virology. 2020 Academic Article GET IT
Times cited: 28
SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. Journal of virology. 2019 Academic Article GET IT
Times cited: 5
Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. Journal of virology. 2019 Academic Article GET IT
Times cited: 14
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature communications. 2019 Academic Article GET IT
Times cited: 161
Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell host & microbe. 2019 Academic Article GET IT
Times cited: 42
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature communications. 2019 Academic Article GET IT
Times cited: 120
Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells. PloS one. 2019 Academic Article GET IT
Times cited: 21
Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. Nature communications. 2019 Academic Article GET IT
Times cited: 27
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. Journal of pharmaceutical sciences. 2019 Academic Article GET IT
Times cited: 20
Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. The Journal of biological chemistry. 2019 Academic Article GET IT
Times cited: 19
Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of virology. 2019 Academic Article GET IT
Times cited: 61
Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell reports. 2018 Academic Article GET IT
Times cited: 102
Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. Journal of virology. 2018 Academic Article GET IT
Times cited: 37
Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 22
Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. Journal of virology. 2018 Academic Article GET IT
Times cited: 69
Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 94
Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Journal of proteome research. 2018 Academic Article GET IT
Times cited: 20
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnology and bioengineering. 2017 Academic Article GET IT
Times cited: 66
Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 32
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 26
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. The Journal of experimental medicine. 2017 Academic Article GET IT
Times cited: 159
Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell reports. 2017 Academic Article GET IT
Times cited: 138
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PloS one. 2017 Academic Article GET IT
Times cited: 14
Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature. 2017 Academic Article GET IT
Times cited: 204
Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 42
Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Journal of virology. 2017 Academic Article GET IT
Times cited: 29
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 78
Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. Proteins. 2017 Academic Article GET IT
Times cited: 7
Publishing: Journals, do your own formatting. Nature. 2017 Article GET IT
Times cited: 5
Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. Journal of virology. 2017 Academic Article GET IT
Times cited: 74
Native-like Env trimers as a platform for HIV-1 vaccine design. Immunological reviews. 2017 Information Resource GET IT
Times cited: 202
Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell reports. 2016 Academic Article GET IT
Times cited: 142
HIV's Achilles' Heel. Scientific American. 2016 Academic Article GET IT
Times cited: 6
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature microbiology. 2016 Academic Article GET IT
Times cited: 131
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 350
Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 123
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 236
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell reports. 2016 Academic Article GET IT
Times cited: 228
Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins. Journal of virology. 2015 Academic Article GET IT
Times cited: 27
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity. 2015 Academic Article GET IT
Times cited: 170
Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Journal of virology. 2015 Academic Article GET IT
Times cited: 30
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015 Academic Article GET IT
Times cited: 230
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 87
What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. Journal of virology. 2015 Academic Article GET IT
Times cited: 24
Another HIV vaccine failure: where to next?. Nature medicine. 2013 Article GET IT
Times cited: 16
Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. Journal of virology. 2012 Academic Article GET IT
Times cited: 62
HIV-1 Env antibodies: are we in a bind or going blind?. Nature medicine. 2012 Article GET IT
Times cited: 7
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 235
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. Journal of virology. 2011 Academic Article GET IT
Times cited: 55
The use of nonhuman primate models in HIV vaccine development. PLoS medicine. 2008 Academic Article GET IT
Times cited: 88
A plea for justice for jailed medical workers. Science (New York, N.Y.). 2006 Article GET IT
Times cited: 4
Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells. The Journal of infectious diseases. 2005 Article GET IT
Times cited: 1
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology. 2004 Academic Article GET IT
Times cited: 33
Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. Journal of virology. 2003 Academic Article GET IT
Times cited: 36
Inhibiting sexual transmission of HIV-1 infection. Nature reviews. Microbiology. 2003 Information Resource GET IT
Times cited: 455
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. Journal of virology. 2003 Academic Article GET IT
Times cited: 63
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood. 2003 Academic Article GET IT
Times cited: 108
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. Journal of virology. 2002 Academic Article GET IT
Times cited: 149
HIV tropism and CD4+ T-cell depletion. Nature medicine. 2002 Article GET IT
Times cited: 24
AIDS vaccine models: challenging challenge viruses. Nature medicine. 2002 Academic Article GET IT
Times cited: 177
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. Journal of virology. 2002 Academic Article GET IT
Times cited: 128
Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. Journal of virology. 2002 Academic Article GET IT
Times cited: 46
A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. Journal of virology. 2002 Academic Article GET IT
Times cited: 56
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. Journal of virology. 2001 Academic Article GET IT
Times cited: 723
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. Journal of virology. 2001 Academic Article GET IT
Times cited: 159
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of virology. 2001 Academic Article GET IT
Times cited: 627
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. Journal of virology. 2001 Information Resource GET IT
Times cited: 111
HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry. AIDS research and human retroviruses. 2001 Academic Article GET IT
Times cited: 16
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of virology. 2001 Academic Article GET IT
Times cited: 237
Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. Journal of virology. 2000 Academic Article GET IT
Times cited: 59
HIV: much at stake with kidneys?. Journal of the American Society of Nephrology : JASN. 2000 Editorial Article GET IT
The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunological reviews. 2000 Information Resource GET IT
Times cited: 246
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. The Journal of infectious diseases. 2000 Academic Article GET IT
Times cited: 68
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. Journal of virology. 2000 Academic Article GET IT
Times cited: 159
Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. Journal of virology. 2000 Academic Article GET IT
Times cited: 102
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 432
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology. 2000 Academic Article GET IT
Times cited: 39
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. The Journal of infectious diseases. 2000 Academic Article GET IT
Times cited: 43
Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS (London, England). 2000 Academic Article GET IT
Times cited: 73
A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. Journal of virology. 1999 Academic Article GET IT
Times cited: 121
Viral phenotype and CCR5 genotype. Nature medicine. 1999 Article GET IT
Times cited: 3
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (London, England). 1999 Academic Article GET IT
Times cited: 424
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. Journal of virology. 1999 Academic Article GET IT
Times cited: 175
HIV. See a pocket, block it. Nature. 1999 Article GET IT
Times cited: 7
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. The Journal of clinical investigation. 1999 Academic Article GET IT
Times cited: 220
HIV-1 entry inhibitors: evading the issue. Nature medicine. 1999 Article GET IT
Times cited: 93
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of virology. 1999 Academic Article GET IT
Times cited: 236
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. The Journal of infectious diseases. 1999 Academic Article GET IT
Times cited: 164
HIV vaccines. Magic of the occult?. Science (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 23
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS (London, England). 1999 Information Resource GET IT
Times cited: 278
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. Journal of virology. 1998 Academic Article GET IT
Times cited: 70
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. Journal of virology. 1998 Academic Article GET IT
Times cited: 145
Clinical trials of HIVIG. The Journal of infectious diseases. 1998 Article GET IT
HIV. Envelope's letters boxed into shape. Nature. 1998 Article GET IT
Times cited: 40
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. Journal of virology. 1998 Academic Article GET IT
Times cited: 286
Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS research and human retroviruses. 1998 Academic Article GET IT
Times cited: 81
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. AIDS research and human retroviruses. 1998 Academic Article GET IT
Times cited: 47
Why do we not have an HIV vaccine and how can we make one?. Nature medicine. 1998 Academic Article GET IT
Times cited: 104
Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. Journal of virology. 1998 Academic Article GET IT
Times cited: 124
Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. Journal of virology. 1998 Academic Article GET IT
Times cited: 31
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nature medicine. 1998 Academic Article GET IT
Times cited: 366
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. Journal of virology. 1998 Academic Article GET IT
Times cited: 66
Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS research and human retroviruses. 1998 Academic Article GET IT
Times cited: 51
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. Journal of virology. 1998 Academic Article GET IT
Times cited: 207
A new classification for HIV-1. Nature. 1998 Article GET IT
Times cited: 730
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature medicine. 1998 Academic Article GET IT
Times cited: 716
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. Journal of virology. 1998 Academic Article GET IT
Times cited: 208
Different subtypes of HIV-1 and cutaneous dendritic cells. Science (New York, N.Y.). 1997 Article GET IT
Times cited: 17
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. The Journal of experimental medicine. 1997 Academic Article GET IT
Times cited: 340
Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. Journal of virology. 1997 Academic Article GET IT
Times cited: 80
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. Journal of virology. 1997 Academic Article GET IT
Times cited: 79
An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS research and human retroviruses. 1997 Academic Article GET IT
Times cited: 31
Co-receptors for HIV-1 entry. Current opinion in immunology. 1997 Information Resource GET IT
Times cited: 476
HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS research and human retroviruses. 1997 Information Resource GET IT
Times cited: 53
HIV-cell fusion. The viral mousetrap. Nature. 1997 Article GET IT
Times cited: 64
Coreceptors: implications for HIV pathogenesis and therapy. Science (New York, N.Y.). 1997 Information Resource GET IT
Times cited: 223
Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. Journal of molecular biology. 1997 Academic Article GET IT
Times cited: 50
Large induction of c-Myc is not essential for the mitogenic response of Swiss 3T3 fibroblasts. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 11
Demonstration of peripheral fucose units in N-linked glycans of human immunodeficiency virus type 1 gp 120: effects on glycoprotein conformation. Archives of virology. 1997 Academic Article GET IT
Times cited: 11
Determining neutralization serotypes of HIV type 1 by neural networks. AIDS research and human retroviruses. 1996 Academic Article GET IT
Times cited: 13
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996 Academic Article GET IT
Times cited: 983
Chemoattractants attract HIV researchers. The Journal of experimental medicine. 1996 Article GET IT
Times cited: 11
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996 Academic Article GET IT
Times cited: 2906
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of virology. 1996 Academic Article GET IT
Times cited: 1036
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of virology. 1996 Academic Article GET IT
Times cited: 208
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of virology. 1996 Academic Article GET IT
Times cited: 144
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Journal of virology. 1995 Academic Article GET IT
Times cited: 467
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. Journal of virology. 1995 Academic Article GET IT
Times cited: 385
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. The Journal of experimental medicine. 1995 Academic Article GET IT
Times cited: 314
Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. Journal of immunology (Baltimore, Md. : 1950). 1995 Academic Article GET IT
Times cited: 95
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. Journal of virology. 1995 Academic Article GET IT
Times cited: 116
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. Journal of virology. 1995 Academic Article GET IT
Times cited: 27
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS (London, England). 1995 Information Resource GET IT
Times cited: 196
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of virology. 1995 Academic Article GET IT
Times cited: 392
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. Journal of virology. 1994 Academic Article GET IT
Times cited: 111
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 185
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (New York, N.Y.). 1994 Academic Article GET IT
Times cited: 998
Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 83
Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. Journal of virology. 1994 Academic Article GET IT
Times cited: 153
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. Journal of virology. 1994 Academic Article GET IT
Times cited: 59
Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. Journal of virology. 1994 Academic Article GET IT
Times cited: 56
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 426
Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS research and human retroviruses. 1994 Academic Article GET IT
Times cited: 164
Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. Journal of acquired immune deficiency syndromes. 1994 Academic Article GET IT
Times cited: 25
Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. Journal of virology. 1994 Academic Article GET IT
Times cited: 25
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. Journal of virology. 1994 Academic Article GET IT
Times cited: 242
Antigenic variation in gp120s from molecular clones of HIV-1 LAI. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 33
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. Journal of virology. 1993 Academic Article GET IT
Times cited: 308
Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 43
The role of CD4 in HIV binding and entry. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 1993 Information Resource GET IT
Times cited: 88
Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 1993 Academic Article GET IT
Times cited: 8
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. Journal of virology. 1993 Academic Article GET IT
Times cited: 113
Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. Journal of virology. 1993 Academic Article GET IT
Times cited: 137
A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 18
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. Journal of virology. 1993 Academic Article GET IT
Times cited: 587
A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1. Journal of virology. 1993 Academic Article GET IT
Times cited: 19
Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 79
The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 40
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. Journal of virology. 1993 Academic Article GET IT
Times cited: 209
Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 28
A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. Journal of virology. 1992 Academic Article GET IT
Times cited: 128
Antigenicity of the HIV-2 V3 loop. AIDS (London, England). 1992 Article GET IT
Times cited: 1
Complementation of human immunodeficiency virus glycoprotein mutations in trans. The Journal of general virology. 1992 Academic Article GET IT
Times cited: 12
Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS research and human retroviruses. 1992 Academic Article GET IT
Times cited: 178
Twin-Site ELISAs for fos and myc Oncoproteins Using the AMPAK System. Methods in molecular biology (Clifton, N.J.). 1992 Academic Article GET IT
Twin-Site ELISAs for fos and myc Oncoproteins Using the AMPAK System. Methods in molecular biology (Clifton, N.J.). 1992 Academic Article GET IT
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of virology. 1992 Academic Article GET IT
Times cited: 288
c-myc protein expression in untransformed fibroblasts. Oncogene. 1991 Academic Article GET IT
Times cited: 159
Immunological incompetence in AIDS. AIDS (London, England). 1991 Article GET IT
Times cited: 4
HIV infectivity. Nature. 1991 Article GET IT
Times cited: 13
Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. Virology. 1991 Academic Article GET IT
Times cited: 32
The role of the V3 loop of gp120 in HIV infection. AIDS (London, England). 1991 Information Resource GET IT
Times cited: 157
GTP gamma S inhibits early c-myc protein accumulation but not DNA synthesis in Swiss 3T3 fibroblasts. FEBS letters. 1990 Academic Article GET IT
Times cited: 3
HIV-1 envelope protein gp120 expression by secretion in E. coli: assessment of CD4 binding and use in epitope mapping. Journal of virological methods. 1990 Academic Article GET IT
Times cited: 19
Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. AIDS research and human retroviruses. 1990 Academic Article GET IT
Times cited: 59
Induction of c-fos protein by activation of vasopressin receptors in smooth muscle cells. FEBS letters. 1989 Academic Article GET IT
Times cited: 13
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (London, England). 1989 Academic Article GET IT
Times cited: 68
Dissociation of c-fos induction from protein kinase C-independent mitogenesis in Swiss 3T3 cells. Oncogene research. 1989 Academic Article GET IT
Times cited: 9
Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS research and human retroviruses. 1988 Academic Article GET IT
Times cited: 69
Ca2+ and pH responses to sequential additions of mitogens in single 3T3 fibroblasts: correlations with DNA synthesis. The Journal of biological chemistry. 1988 Academic Article GET IT
Times cited: 48
C-fos gene activation in murine thymocytes by a mechanism independent of protein kinase C or a Ca2+ signal. FEBS letters. 1988 Academic Article GET IT
Times cited: 4
A sensitive enzyme-linked immunosorbence assay for the c-fos and v-fos oncoproteins. Biochimica et biophysica acta. 1988 Academic Article GET IT
Times cited: 6
Differential induction of c-fos and c-myc by cyclic AMP in Swiss 3T3 cells: significance for the mitogenic response. Oncogene research. 1988 Academic Article GET IT
Times cited: 18
Immunological probes in the analysis of myc protein expression. Current topics in microbiology and immunology. 1988 Academic Article GET IT
Times cited: 10
Synergistic signals in the mechanism of antigen-induced exocytosis in 2H3 cells: evidence for an unidentified signal required for histamine release. The Journal of cell biology. 1987 Academic Article GET IT
Times cited: 84
Extraction and recovery of inositol phosphates from tissues. The Biochemical journal. 1987 Article GET IT
Times cited: 76
Calcium regulates inositol 1,3,4,5-tetrakisphosphate production in lysed thymocytes and in intact cells stimulated with concanavalin A. The EMBO journal. 1987 Academic Article GET IT
Times cited: 36
The early mitogenic pathway in mouse thymocytes: an analysis of the dual signal hypothesis. Advances in experimental medicine and biology. 1987 Academic Article GET IT
Times cited: 1
Calcium and cell proliferation. British medical bulletin. 1986 Information Resource GET IT
Times cited: 74
c-fos and c-myc gene activation, ionic signals, and DNA synthesis in thymocytes. The Journal of biological chemistry. 1986 Academic Article GET IT
Times cited: 77
A common sequence of calcium and pH signals in the mitogenic stimulation of eukaryotic cells. Nature. 1985 Academic Article GET IT
Times cited: 301
Early response pattern analysis of the mitogenic pathway in lymphocytes and fibroblasts. Journal of cell science. Supplement. 1985 Information Resource GET IT
Times cited: 31
Mitogens increase phosphorylation of phosphoinositides in thymocytes. Nature. 1984 Academic Article GET IT
Times cited: 148
Calcium signals and phospholipid methylation in eukaryotic cells. The Biochemical journal. 1984 Academic Article GET IT
Times cited: 26
The calcium signal and phosphatidylinositol breakdown in 2H3 cells. The Journal of biological chemistry. 1984 Academic Article GET IT
Times cited: 182
The mechanism of the calcium signal and correlation with histamine release in 2H3 cells. The Journal of biological chemistry. 1984 Academic Article GET IT
Times cited: 304
Large effects of preparative techniques on lymphocyte cyclic AMP content. The Biochemical journal. 1983 Academic Article GET IT
Times cited: 10
The bivalent-cation dependence of phosphatidylinositol synthesis in a cell-free system from lymphocytes. The Biochemical journal. 1983 Academic Article GET IT
Times cited: 4
Free cytoplasmic calcium concentration and the mitogenic stimulation of lymphocytes. The Journal of biological chemistry. 1983 Academic Article GET IT
Times cited: 340
Early increases in phospholipid methylation are not necessary for the mitogenic stimulation of lymphocytes. The Journal of biological chemistry. 1982 Academic Article GET IT
Times cited: 21

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Targeting germline-bNAbs via SOSIP trimers; awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2026 - 2031
Neutralization of primary HIV-1 viruses awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2023 - 2028
INV091003 Targeting germline-bNAbs via SOSIP trimers awarded by Bill & Melinda Gates Foundation Principal Investigator 2025 - 2026
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2020 - 2026
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2021 - 2022

An early life multivalent immunization strategy for induction of neutralization breadth awarded by National Institute of Allergy & Infectious Diseases Co-Principal Investigator 2025 - 2030
Translating germline-targeting HIV Env SOSIP immunization of infants: targeting bnAbs in early life awarded by National Institute of Allergy & Infectious Diseases Co-Principal Investigator 2025 - 2030

INV63951 - Trimer based germline-targeting immunization to induce HIV-1 bNAbs - AUMC awarded by Bill & Melinda Gates Foundation Principal Investigator Subaward 2025 - 2026

more ...

less ...

Background

education and training

Ph.D., Cambridge University (United Kingdom) 1982
M.A., Cambridge University (United Kingdom) 1981
B.A., Downing College (United Kingdom) 1978

Contact

full name

John P Moore

primary email

jpm2003@med.cornell.edu

VIVO Weill Cornell Medical College

John P Moore Professor of Microbiology and Immunology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email